

Catabasis Pharmaceuticals adds \$14.5M to Series A financing

Mass High Tech: The Journal of New England Technology

Catabasis Pharmaceuticals Inc., a Cambridge biopharmaceutical company focused on inflammatory and metabolic diseases, has raised \$14.5 million in a second tranche of a Series A funding round led by SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures, with additional backing from Advanced Technology Ventures. The Series A financing originally closed with [\\$39.6 million in April](#) [1].

The second tranche of financing stems from development milestones Catabasis reached, in leading to human clinical trials, for its drug candidate to treat type 2 diabetes. The funds will support this compound in reaching human clinical trials in 2011, in addition to supporting the company's metabolic disease and inflammation programs.

[SOURCE](#) [2]

Source URL (retrieved on 01/26/2015 - 7:02pm):

http://www.mdtmag.com/news/2010/12/catabasis-pharmaceuticals-adds-145m-series-financing?qt-recent_content=0

Links:

[1] <http://www.masshightech.com/stories/2010/04/19/daily18-Catabasis-closes-40M-Series-A-financing-round.html>

[2] <http://www.masshightech.com/stories/2010/12/06/daily29-Catabasis-Pharmaceuticals-adds-145M-to-Series-A-financing.html>